Nanoparticle-Based Therapeutic Strategies for Pathological Cardiac Hypertrophy: Preclinical Advances, Translational Challenges, and Future Perspectives Authors: Mengyue Yang, Jinhui Wu Published: 2026 ABSTRACT AbstractPathological cardiac hypertrophy is a major contributor to heart failure and is characterized by complex molecular mechanisms involving transcriptional and epigenetic regulation, signal transduction, metabolic remodeling, inflammatory responses, and extracellular matrix remodeling. Although conventional pharmaceutical treatments may alleviate the progression of cardiac hypertrophy, their clinical effectiveness is limited by poor cardiac selectivity, systemic side effects, and limited efficacy in reverseing pathological remodeling. Recently, nanoparticle-based strategies have emerged as a promising therapeutic approach for cardiac hypertrophy owing to their ability to enhance cardiac-targeted drug delivery, enable controlled or stimuli-responsive drug release, and reduce off-target toxicity through improved biodistribution. This review systematically summarizes the design strategies of nanoparticle-based therapies for pathological cardiac hypertrophy, including material platforms such as inorganic, organic, and biomimetic nanoparticles, key delivery strategies such as passive targeting, active targeting, biomimetic targeting, and stimulus-responsive release, and administration routes including intravenous, intraperitoneal, intradermal, inhalation, and oral administration. In addition, this review provides a comprehensive summary of the preclinical applications of the above strategies in the fields of gene and epigenetic regulation, antioxidant, anti-inflammatory, and anti-fibrotic treatments. Finally, this review analyzes the challenges in clinical translation on the basis of critical issues, including long-term biosafety, insufficient targeting efficacy, large-scale production, and appropriate administration routes. Introduction Pathological cardiac hypertrophy is a detrimental cardiac remodeling process triggered by various pathological stimuli, including persistent pressure or volume overload, abnormal activation of the neurohumoral system, and myocardial ischemia and hypoxia, as well as genetic abnormalities such as storage disease and hypertrophic cardiomyopathy (Figure 1).1 The key features of cardiac hypertrophy include an elevated volume of cardiomyocytes, alteration of the extracellular matrix, and compromised cardiac contraction and relaxation capabilities.2 Pathological cardiac hypertrophy has been observed in various cardiovascular diseases and typically results in severe consequences, including heart failure, arrhythmia, and even sudden death.3–5 According to the report from the American Heart Association in 2023, cardiovascular diseases remain one of the leading causes of death in the United States and globally, imposing a heavy burden on public health and the healthcare system.6 Left ventricular hypertrophy (LVH) is the predominant structural remodeling of pathological cardiac hypertrophy and affects approximately 10–20% of the general adult population worldwide,7 with the prevalence increasing to 36–41% among patients with hypertension.8 LVH is an independent predictor of adverse cardiovascular outcomes. A prospective study demonstrated that the risk factor-adjusted hazard ratio (HR) for sudden death was 2.16 in LVH patients compared with those without LVH.9 In addition, a meta-analysis reported that LVH was associated with a 2.16-fold higher risk of non-fatal cardiovascular events and a 2.58-fold higher risk of cardiovascular mortality.10 Figure 1Etiology of pathological cardiac hypertrophy and the therapeutic potential of nanoparticle-based treatments (created with BioRender.com). Cardiac hypertrophy arises from diverse stimuli such as pressure overload, neurohumoral activation, and genetic mutations and can progress to heart failure. Traditional treatments offer low cost and an established safety profile but are limited by side effects and inadequate reversal of hypertrophy. Nanoparticle-based treatments enable targeted delivery, stimuli-responsive release, and potential reversal of remodeling, but their high cost and preclinical status remain major translational hurdles.A diagram illustrating the causes and treatments of pathological hypertrophy. The top section lists causes: pressure overload (hypertension, aortic stenosis), volume overload (aortic regurgitation, mitral regurgitation), neurohumoral factors (angiotensin II, catecholamine), ischemia/hypoxia (myocardial infarction, COPD), storage diseases (glycogen, misfolded protein) and hypertrophic cardiomyopathy (MYH7, MYBPC3). An arrow points from these causes to pathological hypertrophy, depicted with a heart image, leading to heart failure. Below, two treatment options are shown. Traditional treatments have advantages: low cost, established safety profile and limitations: side effects, limited reversibility. Nanoparticle-based treatments offer advantages: targeted delivery, stimuli-responsive release, potential to reverse hypertrophy and limitations: costly, preclinical stage.A diagram of pathological hypertrophy causes and treatments, showing progression to heart failure.Abbreviations: COPD, chronic obstructive pulmonary disease; MYH7, myosin heavy chain 7; MYBPC3, myosin binding protein C3. Etiology of pathological cardiac hypertrophy and the therapeutic potential of nanoparticle-based treatments (created with BioRender.com). Cardiac hypertrophy arises from diverse stimuli such as pressure overload, neurohumoral activation, and genetic mutations and can progress to heart failure. Traditional treatments offer low cost and an established safety profile but are limited by side effects and inadequate reversal of hypertrophy. Nanoparticle-based treatments enable targeted delivery, stimuli-responsive release, and potential reversal of remodeling, but their high cost and preclinical status remain major translational hurdles. Pathological cardiac hypertrophy can be categorized into concentric and eccentric hypertrophy. Concentric hypertrophy typically occurs in response to pressure overload and is characterized by increased ventricular wall thickness and decreased chamber size. Eccentric hypertrophy is more common in response to volume overload and is characterized by dilatation of the ventricular chamber and thinning of the wall.1 The concentric hypertrophy induced by pressure overload preferentially involves activation of signaling pathways such as mitogen-activated protein kinase (MAPK), calcineurin, and β-arrestin-2, as well as more severe cardiac fibrosis and cardiomyocyte death.11,12 Eccentric hypertrophy due to volume overload preferentially involves activation of signaling pathways, including protein kinase B (Akt) and calmodulin-dependent protein kinase II (CaMKII), with less fibrosis and apoptosis and more evident angiogenesis.12 In conclusion, the two phenotypes of cardiac hypertrophy exhibit distinct patterns of preferentially activated pathways, indicating that anti-hypertrophic therapies may target the underlying signaling pathways based on their unique phenotypes. Traditional treatments for pathological cardiac hypertrophy mainly include β-blockers, calcium channel antagonists, renin-angiotensin-aldosterone system (RAAS) inhibitors, and sodium-glucose cotransporter 2 inhibitors.13 Despite their low cost and established safety profile, these pharmacological therapies often lack cardiac specificity, and the systemic side effects cannot be ignored. Depending on the specific category of the drugs, systemic adverse side effects mainly include hypotension, bradycardia, electrolyte disturbances, and urinary tract infections.14,15 Importantly, current pharmacological therapies mainly relieve hemodynamic overload and neurohormonal activation rather than directly regulating the molecular mechanisms underlying pathological cardiac hypertrophy. As a result, their ability to reverse established pathological cardiac remodeling remains limited. Moreover, the small-molecule drugs also exhibit limited intrinsic cardiac specificity.16 The cellular uptake occurs predominantly via passive diffusion across biological membranes in a non-selective manner. Consequently, cardiac distribution is largely governed by regional perfusion rather than active uptake by cardiomyocytes. Furthermore, cardiac delivery of conventional pharmaceuticals is impeded by various pharmacokinetic hurdles, including hepatic first-pass metabolism following oral administration and fast systemic clearance caused by short plasma half-lives, consequently limiting local bioavailability and therapeutic efficacy.17 Moreover, surgical and device therapies including aortic valve replacement surgery18,19 and left ventricular assist device therapy20,21 are often used to correct hemodynamic abnormalities and relieve cardiac hypertrophy. However, they are only applicable to patients with specific indications and have difficulty intervening in pathological cardiac hypertrophy at the molecular level. Hence, the development of new treatments for cardiac hypertrophy is an urgent issue. Nanoparticle-based therapies have recently emerged as a novel therapeutic method for cardiac hypertrophy. Many therapeutic agents, such as small molecule medications,22 nucleic acids,23 proteins,24 and peptides,25 can be delivered by nanoparticles. In addition, by achieving cardiac targeting and exhibiting controlled release in diseased regions, nanoparticles may enhance drug accumulation while reducing systemic side effects. Figure 1 illustrates the principal etiologies of pathological cardiac hypertrophy and compares traditional treatments with nanoparticle-based treatments. It highlights the key advantages of nanoparticle-based treatments, including targeted drug delivery, stimuli-responsive release, and the potential to reverse cardiac hypertrophy. In addition to enhancing the efficiency of targeted drug delivery, the nanoparticle-based delivery systems can also overcome the limitations of free drugs by controlling the drug release behaviors and optimizing the drug exposure characteristics.26 The free drugs generally lack the protection and drug release regulation mechanisms, and many therapeutic agents have a limited systemic half-life due to the rapid distribution, metabolism, and clearance.27 Therefore, the plasma drug concentrations usually peak shortly after administration and subsequently decrease, which makes it difficult to maintain the therapeutic concentrations over time and increases the risk of adverse effects associated with peak drug concentrations.28 Conversely, nanoparticle-based delivery systems can protect therapeutic agents through drug encapsulation, structural engineering, and surface modification strategies, thus enabling controlled drug release.29 As conceptually illustrated in Figure 2, under ideal design conditions, nanoparticle-based systems can transform the rapid release profile of free drugs to a slower and sustained release profile.29 Thus, the plasma concentration-time profile can be theoretically shifted from the sharp peak and rapid decline observed with free drugs to a more stable exposure pattern with reduced peak concentrations, slow elimination, and prolonged maintenance within the therapeutic window.30 This modulation not only reduces the risk of toxicity associated with peak concentrations but also enables sustained drug exposure within the therapeutic range, thereby improving therapeutic efficacy and enhancing the overall safety profile. Figure 2Theoretical schematic of nanoparticle-based controlled drug release and its potential impact on therapeutic efficacy and safety (created with BioRender.com). This is an idealized conceptual model of controlled drug release using nanoparticles. Compared with free drugs, which show rapid release and a sharp peak in plasma drug concentration followed by rapid decline, nanoparticle-based delivery systems can offer a slower and more sustained drug release profile under optimized design conditions. Hence, the plasma concentration-time profile is characterized by lower peak drug concentrations, prolonged maintenance within the therapeutic window, and a more gradual decline in drug concentration. Controlled drug release from nanoparticles has the potential to improve therapeutic efficacy and the overall safety profile by minimizing burst release and peak concentration-associated toxicity while maintaining sustained therapeutic drug exposure.A line graph showing cumulative drug release over time for free drug and nanoparticle-based delivery. The free drug shows rapid release reaching 100 percent quickly, while nanoparticle-based delivery shows a slower, sustained release. Another graph depicts drug concentration in plasma over time. The free drug shows a sharp peak exceeding the toxicity threshold, followed by a rapid decline. Nanoparticle-based delivery maintains concentration within the therapeutic window, showing a gradual decline. Icons illustrate free drug characteristics: burst release, shorter circulation time, higher toxicity risk. Nanoparticles show controlled release, prolonged circulation, improved safety profile.Two graphs compare free drug and nanoparticle-based delivery in drug release and plasma concentration over time. Theoretical schematic of nanoparticle-based controlled drug release and its potential impact on therapeutic efficacy and safety (created with BioRender.com). This is an idealized conceptual model of controlled drug release using nanoparticles. Compared with free drugs, which show rapid release and a sharp peak in plasma drug concentration followed by rapid decline, nanoparticle-based delivery systems can offer a slower and more sustained drug release profile under optimized design conditions. Hence, the plasma concentration-time profile is characterized by lower peak drug concentrations, prolonged maintenance within the therapeutic window, and a more gradual decline in drug concentration. Controlled drug release from nanoparticles has the potential to improve therapeutic efficacy and the overall safety profile by minimizing burst release and peak concentration-associated toxicity while maintaining sustained therapeutic drug exposure. Nonetheless, the nanoparticle-based delivery system is still facing significant challenges in the treatment of pathological cardiac hypertrophy. Firstly, the long-term biosafety of nanoparticles remains unclear, largely because most nanoparticle-based therapeutic strategies are still at the preclinical stage and lack sufficient long-term clinical safety data. Their potential toxicity and long-term accumulation are particularly concerning.31,32 Secondly, hypertrophic myocardium lacks the typical enhanced permeability and retention effects,33,34 as well as the formation of a protein corona,35 limiting the efficient accumulation of nanoparticles in the cardiac tissue. Thirdly, the large-scale production of nanoparticles is limited by significant batch-to-batch variations,36 complex and costly preparation processes,37 and the absence of quality control standards. In addition, the administration route of nanoparticles is mainly intravenous injection. Long-term and repeated administration may reduce patient compliance. Alternative routes such as oral administration and inhalation still need to be further verified. Despite the existence of multiple publications addressing the molecular mechanisms of pathological cardiac hypertrophy and the development of nanoparticle-based delivery systems, a comprehensive summary that integrates both aspects remains rather scarce. This review systematically summarizes recent advances in nanoparticle-based delivery systems, with a particular focus on material platforms, targeting strategies, stimuli-responsive drug release, and preclinical applications. The Molecular and Cellular Mechanisms of Pathological Cardiac Hypertrophy As a crucial pathological process underlying various cardiovascular disorders, pathological cardiac hypertrophy is driven by highly complex molecular and cellular mechanisms.1 Figure 3 illustrates the key pathological mechanisms that contribute to cardiac hypertrophy, including fetal gene reactivation,38,39 activation of hypertrophic signal transduction pathways,2 metabolic remodeling,40 inflammatory responses,41,42 and extracellular matrix remodeling.43 Moreover, nanoparticle-based therapeutic strategies were also described in Figure 3, including gene and epigenetic nanotherapy, anti-oxidative nanotherapy, anti-inflammatory nanotherapy, and anti-fibrotic nanotherapy. By precisely intervening in specific pathological processes, nanoparticle-based therapeutic strategies offer the potential to alleviate pathological cardiac hypertrophy at the molecular level, providing new strategies and directions for the treatment of pathological cardiac hypertrophy.25,44,45 Figure 3Key mechanisms of pathological cardiac hypertrophy and nanoparticle-based therapeutic strategies (created with BioRender.com). Pathological cardiac hypertrophy is regulated by multiple mechanisms, including transcription and epigenetic regulation, signal transduction, metabolic remodeling, inflammation, and extracellular matrix (ECM) remodeling. Additionally, nanoparticle-based therapies mainly include gene and epigenetic nanotherapy, anti-oxidative nanotherapy, anti-inflammatory nanotherapy, and anti-fibrotic nanotherapy. Horizontal arrows indicate cellular transitions. Upward and downward arrows indicate increased and decreased levels of the corresponding molecules, respectively. Cross symbols denote inhibition of pathological processes. Bidirectional arrows indicate crosstalk and reciprocal interactions among these pathological mechanisms.The diagram illustrates pathological cardiac remodeling and nanoparticle-based therapeutic strategies. Central to the image is ′Pathological cardiac remodeling′. Surrounding it are sections: ′Transcription and epigenetic regulation′ with ′Fetal gene reactivation′; ′Signal transduction′ with ′NFAT′, ′MAPK′, ′PI3K/AKT/mTORC1′, ′TGF-beta1/SMAD′; ′Metabolic remodeling′ showing ′Mitochondrial dysfunction′, ′FAO′, ′Glycolysis′; ′Inflammation′ with ′IL-6′, ′IL-1beta′, ′TNF-alpha′; ′ECM remodeling′ with ′Fibroblasts′, ′Collagen I/III′. Anti-fibrotic nanotherapy shows ′Quiescent fibroblasts′ to ′Activated fibroblasts′. Anti-inflammatory nanotherapy shows ′M1 macrophages′ to ′M2 macrophages′, ′TNF-alpha′, ′IL-1beta′, ′IL-6′. Anti-oxidative nanotherapy includes ′ROS scavenging′, ′Mitochondrial repair′. Gene and epigenetic nanotherapy lists ′plasmid DNA′, ′miRNA′, ′siRNA′. Arrows indicate processes and interactions.Diagram of pathological cardiac remodeling and nanoparticle therapies.Abbreviations: ECM, extracellular matrix; NFAT, nuclear factor of activated T cells; MAPK, mitogen-activated protein kinase; PI3K/AKT/mTORC1: phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin complex 1; TGF-β1/SMAD: transforming growth factor-beta 1/suppressor of mothers against decapentaplegic; ROS, reactive oxygen species; FAO, fatty acid oxidation; IL-1β, interleukin-1 beta; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha. Key mechanisms of pathological cardiac hypertrophy and nanoparticle-based therapeutic strategies (created with BioRender.com). Pathological cardiac hypertrophy is regulated by multiple mechanisms, including transcription and epigenetic regulation, signal transduction, metabolic remodeling, inflammation, and extracellular matrix (ECM) remodeling. Additionally, nanoparticle-based therapies mainly include gene and epigenetic nanotherapy, anti-oxidative nanotherapy, anti-inflammatory nanotherapy, and anti-fibrotic nanotherapy. Horizontal arrows indicate cellular transitions. Upward and downward arrows indicate increased and decreased levels of the corresponding molecules, respectively. Cross symbols denote inhibition of pathological processes. Bidirectional arrows indicate crosstalk and reciprocal interactions among these pathological mechanisms. Transcription and Epigenetic Regulation Transcription and epigenetic regulation contribute to the gene expression alterations in pathological cardiac hypertrophy. Among them, one of the most typical alterations is fetal gene reactivation, including Atrial Natriuretic Peptide (ANP), Brain Natriuretic Peptide (BNP), and Beta-Myosin Heavy Chain (β-MHC).38,39 Nuclear factor of activated T cells (NFAT) is recognized as a significant transcription factor in pathological cardiac hypertrophy.46 Calcium signal-dependent calcineurin induces the dephosphorylation of NFAT, promoting its translocation into the nucleus and triggering the transcription of downstream target genes, including hypertrophy-related genes and fetal genes.47,48 Given its central role in pathological hypertrophy and its relatively well-characterized regulatory mechanism, the NFAT pathway represents an attractive candidate for targeted therapeutic intervention. Additionally, myocyte enhancer factor 2 (MEF2) functions as a central node in multiple signaling pathway networks, and MEF2 promotes the transcription of hypertrophy-associated genes by synergy with NFAT and GATA4.49 MEF2 acetylation is essential for the activation of hypertrophy-related gene expression, while class IIa histone deacetylases (HDACs) suppress MEF2 activity.50 Blocking MEF2 acetylation is a highly promising target for nanoparticle-based therapies in reversing cardiac hypertrophy.50 Another essential transcription factor, GATA binding protein 4 (GATA4), is highly expressed in cardiomyocytes. Accumulating evidence indicates that GATA4 is indispensable in the reactivation of fetal genes in pathological cardiac hypertrophy.51,52 However, GATA4 also contributes to the survival of cardiomyocytes and the maintenance of normal cardiac function.53 Inhibition of GATA4 may cause potential safety challenges. In contrast to the aforementioned pro-hypertrophic transcription factors (NFAT, MEF2, and GATA4), forkhead box protein O1 (FOXO1) exerts context-dependent effects on hypertrophic remodeling by regulating stress adaptation and metabolic homeostasis. Moderate FOXO1 activity generally exerts anti-hypertrophic effects, while sustained FOXO1 activation may promote cardiac hypertrophy.54 Therefore, therapeutic modulation of FOXO1 may require precise control of its activation intensity and duration rather than complete inhibition. Collectively, NFAT- and MEF2-associated networks may represent promising targets for nanoparticle-based therapies, whereas GATA4 and FOXO1 may require more selective and spatiotemporally controlled delivery to enhance efficacy and reduce off-target effects. Alongside transcription factor-mediated regulation, the role of epigenetic regulation cannot be overlooked. In pathological cardiac hypertrophy, histone modifications such as acetylation, methylation, lactylation, and ubiquitination are involved in regulating hypertrophy-related gene expression.55–58 Among these modifications, histone acetylation has drawn particular interest owing to its recognition by epigenetic reader proteins, such as bromodomain-containing protein 4 (BRD4), which governs enhancer activity and drives hypertrophic gene transcription.59 For instance, the BRD4 inhibitor JQ1 has shown anti-hypertrophic effects in preclinical models, providing a rationale for the development of BRD4-targeted nanoparticle-based strategies.22 Moreover, DNA methylation has been extensively investigated for its role in regulating hypertrophy-related gene expression and contributing to the progression of cardiac hypertrophy.60,61 However, therapeutic modulation of DNA methylation is still challenging, because DNA methylation patterns influence broad genomic programs beyond hypertrophy-associated pathways.62 Therefore, precise and disease-specific control of DNA methylation is a major challenge for nanoparticle-based therapeutic strategies. Furthermore, non-coding RNA is an important post-transcriptional and epigenetic regulatory factor in pathological cardiac hypertrophy.63 Among them, microRNAs (miRNAs) mainly bind with the 3’ non-translated region of target mRNAs, inhibiting the translation or promoting the degradation of mRNA, thereby regulating the expression of genes related to hypertrophy.64,65 Long non-coding RNAs (lncRNAs) act as miRNA sponges through the competitive endogenous RNA (ceRNA) mechanism, regulating the expression of downstream genes.66 Due to their ability to precisely regulate disease-associated gene networks through specific molecular interactions, miRNAs and lncRNAs provide promising potential for nanoparticle-based therapies.67 Nanoparticle-based therapies have been employed to modulate the lncRNA/miRNA regulatory network and have demonstrated therapeutic effects in pathological cardiac hypertrophy. For example, neutrophil membrane-coated mesoporous silica nanoparticles have been applied to deliver siRNA of lncRNA AAB, a known sponge of miR-30b-5p. In a rat model of cardiac hypertrophy, this nanoparticle was given via intravenous injection at a dose of 50 nM siRNA per rat, once every two days over a four-week treatment period. As a result, miR-30b-5p activity was restored, which suppressed ferroptosis in cardiac microvascular endothelial cells and ultimately alleviated the hypertrophic phenotype.67 Furthermore, the above nanoparticles integrate precise targeting, excellent biocompatibility, and biodegradability, thereby providing an effective and safe platform for therapeutic delivery.67 Signal Transduction A number of signal transduction pathways contribute to pathological cardiac hypertrophy, with the NFAT, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin complex 1 (mTORC1) pathway, and MAPK pathways being regarded as the major signaling pathways.13,68 Persistent pathological stimulation results in a prolonged elevation of intracellular calcium concentrations in cardiomyocytes, consequently activating calcineurin. Activated calcineurin dephosphorylates NFAT, facilitating its translocation into the nucleus and directly promoting the reactivation of hypertrophy-related genes and fetal genes.47,48 The NFAT pathway connects pathological signaling to hypertrophic gene transcription and has well-characterized regulatory mechanisms, which makes it a promising target for nanoparticle-based interventions. Additionally, the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin complex 1 (mTORC1) pathway is another central regulator of pathological cardiac hypertrophy. Under pathological stress, PI3K activation results in phosphorylation and activation of AKT, which therefore activates mTORC1 signaling. Activated mTORC1 subsequently phosphorylates downstream effectors, including ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which enhances protein synthesis and promotes cardiomyocyte growth, ultimately leading to pathological cardiac hypertrophy.69,70 The PI3K/AKT/mTORC1 pathway is a direct regulator of cardiomyocyte growth and a potential therapeutic target. However, its broad involvement in systemic physiological growth and metabolism across multiple tissues poses a challenge to the design of selective and spatiotemporally controlled delivery strategies of nanoparticles for therapeutic efficacy with minimal off-target effect.71 Moreover, the MAPK pathway mainly consists of three main pathways, including extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK).72 The MAPK signaling system facilitates cardiac hypertrophy by regulating cardiomyocyte proliferation, apoptosis, and the expression of hypertrophic genes.73 However, its involvement in diverse physiological and pathological processes may complicate selective therapeutic targeting and raise concerns about pathway-wide inhibition.74 Metabolic Remodeling and Mitochondrial Dysfunction Metabolic remodeling is a hallmark of pathological cardiac hypertrophy and an important basis for the decline of cardiac function.1 Metabolic remodeling in pathological cardiac hypertrophy is defined by alterations in substrate use patterns. The capacity for oxidation of the fatty acids is reduced, whereas the extent of glycolysis is relatively increased.75 This switch of metabolism is similar to the cardiac fetal metabolic phenotype and is called fetal-type metabolism.76 Glycolysis is less efficient in energy transformation than fatty acid oxidation, which may contribute to the imbalance of energy supply and demand.40 Mitochondrial dysfunction is another characteristic of metabolic remodeling. Chronic pathological stimulation impairs the efficiency of oxidative phosphorylation and ATP production by dysregulation of mitochondrial autophagy and mitochondrial biogenesis,77 and imbalance in mitochondrial fusion and fission.78 Metabolic remodeling and mitochondrial dysfunction synergistically contribute to excessive production of reactive oxygen species (ROS).79 Excessive ROS not only aggravates mitochondrial injury but also acts as signaling molecules to activate hypertrophic-related signaling pathways, thus forming a vicious cycle to accelerate pathological cardiac remodeling.80 To break this vicious cycle, nanoparticle-based antioxidant delivery has emerged as a promising therapeutic strategy. For example, a ROS-responsive nanoparticle encapsulated with the death receptor 5 fusion protein (sDR5-Fc) was given intravenously in rats (200 μL/dose, twice weekly for 14 days, specific drug loading not provided). This approach permitted sDR5-Fc release and ROS scavenging at the site of myocardial infarction, thereby lowering infarct size, attenuating fibrosis, and inhibiting cardiac hypertrophy.81 Inflammation Previous studies showed that the expression levels of pro-inflammatory factors were increased in hypertrophic cardiac tissue, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6).41,42 Pro-inflammatory factors are generated not just by immune cells but also by cardiomyocytes and fibroblasts.82 These cytokines increase the expression of genes associated with cardiac hypertrophy directly via the activation of signaling pathways such as nuclear factor kappa-B (NF-κB) and MAPK.83,84 Particularly, macrophages are key mediators in cardiac remodeling,85 and they secrete pro-inflammatory and pro-fibrotic mediators, thereby linking cardiac inflammation to hypertrophic remodeling.86,87 Collectively, inflammatory factors work in synergy with immune cells to accelerate the progression of pathological cardiac hypertrophy. Extracellular Matrix Remodeling and Fibrosis Continuous pathogenic stimulation causes excessive deposition and cross-linking of collagen, particularly type I and type III collagen,88,89 which enhances cardiac stiffness, diminishes cardiac compliance, and promotes diastolic dysfunction.90 Cardiac fibroblasts are the primary effector cells in extracellular matrix remodeling. Under pathological stimulation, resting fibroblasts activate and differentiate into α-smooth muscle actin-expressing myofibroblasts, which synthesize and secrete large amounts of ECM proteins, continuously driving myocardial fibrosis and maladaptive remodeling.43 The above pathological process is principally regulated by the transforming growth factor-beta 1 (TGF-β1)/suppressor of mothers against decapentaplegic (Smad) signaling pathway. The expression level of TGF-β1 is proven to be upregulated in the hypertrophic myocardium. Upon ligand binding, TGF-β receptors phosphorylate and activate Smad2/3, which form a complex with Smad4 and translocate to the nucleus. This leads to increased transcription of genes associated with cardiac hypertrophy and fibrosis.91 In addition to excessive ECM production, an imbalance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) further disrupts ECM homeostasis, contributing to abnormal matrix turnover and structural disorganization.92 Nanoparticle‑mediated delivery of antifibrotic agents has demonstrated considerable potential in reducing ECM remodeling and fibrosis. For instance, engineered extracellular vesicles (EVs) loaded with the TGF‑β1 receptor inhibitor GW788388 were administered via tail vein injection at 100 μg of EVs every 3 days for a total of four doses in an isoproterenol‑induced mouse model of cardiac fibrosis. This system effectively suppressed fibroblast activation and attenuated collagen deposition.93 Design Strategies of Nanoparticles in Pathological Cardiac Hypertrophy Biological Barriers of Nanoparticle Delivery in Pathological Cardiac Hypertrophy The therapeutic efficacy of nanoparticle-based therapies for pathological cardiac hypertrophy depends not only on the biological activity of the therapeutic agents but also on the efficiency of their delivery to the myocardium. After systemic administration, the nanoparticles undergo a series of processes that impact the delivery efficiency, including impaired vascular extravasation,44 the formation of protein corona,35 and in vivo clearance30 (Figure 4A). These factors influence the circulation time and the efficiency of cardiac accumulation of the nanoparticles. Figure 4Cardiac delivery barriers and design principles of nanoparticles for cardiac hypertrophy (created with BioRender.com). (A) Major biological barriers limiting cardiac delivery, including impaired vascular extravasation, protein Corona formation, and systemic clearance. (B) Major nanomaterial platforms, including inorganic nanoparticles, organic nanoparticles, and biomimetic nanoparticles. (C) Targeting strategies of nanoparticles, including passive targeting, active targeting achieved through ligand-receptor interactions, and biomimetic targeting based on the properties of natural membranes. (D) stimuli-responsive release strategies. (E) Administration routes, including intravenous injection, intraperitoneal injection, intradermal injection, inhalation, and oral administration.The diagram illustrates various aspects of nanoparticle delivery for cardiac hypertrophy. A shows major biological barriers: impaired vascular extravasation, protein corona formation and systemic clearance. B categorizes nanomaterial platforms into inorganic (Au NPs, MSN), organic (liposome, polymeric NPs) and biomimetic (extracellular vesicles, cell-membrane coated nanoparticles). C depicts targeting strategies: passive targeting, active targeting and biomimetic targeting. D illustrates stimuli-responsive release strategies involving pH and enzymes. E lists administration routes: intravenous injection, intraperitoneal injection, intradermal injection, inhalation and oral administration.Diagram of nanoparticle delivery barriers, platforms, targeting, release and administration routes.Abbreviations: AuNPs, gold nanoparticles; MSN, mesoporous silica nanoparticles; NPs, nanoparticles; ROS, reactive oxygen species; H⁺, hydrogen ions. Cardiac delivery barriers and design principles of nanoparticles for cardiac hypertrophy (created with BioRender.com). (A) Major biological barriers limiting cardiac delivery, including impaired vascular extravasation, protein Corona formation, and systemic clearance. (B) Major nanomaterial platforms, including inorganic nanoparticles, organic nanoparticles, and biomimetic nanoparticles. (C) Targeting strategies of nanoparticles, including passive targeting, active targeting achieved through ligand-receptor interactions, and biomimetic targeting based on the properties of natural membranes. (D) stimuli-responsive release strategies. (E) Administration routes, including intravenous injection, intraperitoneal injection, intradermal injection, inhalation, and oral administration. A major obstacle to nanoparticle accumulation in hypertrophic myocardium is the lack of tumor-like vascular remodeling. Cardiac hypertrophy is characterized by an imbalance between angiogenesis and cardiomyocyte proliferation,94 resulting in microvascular rarefaction and endothelial dysfunction.95,96 As opposed to tumors, which are characterized by aberrant angiogenesis, defective vascular architecture, and impaired lymphatic drainage that contribute to the enhanced permeability and retention (EPR) effect,97 pathological cardiac hypertrophy generally lacks such tumor-like remodeling. Therefore, the typical EPR effect is unlikely to be observed in cardiac hypertrophy,98 which may lead to impaired vascular extravasation. However, the absence of a typical EPR effect does not imply an unchanged vascular permeability. Endothelial dysfunction, inflammatory activation, and microvascular remodeling in pathological cardiac hypertrophy also contribute to altered vascular permeability.99,100 However, these permeability changes are usually less pronounced and less predictable than the classical tumor-associated EPR effect, resulting in insufficient accumulation of nanoparticles.101 Additionally, the fast blood flow, dense extracellular matrix, and continuous mechanical contraction of the heart are all obstacles to the accumulation and retention of nanoparticles.102 In addition, protein corona formation may influence the cardiac targeting efficiency of nanoparticles.35 Nanoparticles adsorb plasma proteins in the circulation, forming a protein corona composed of a stable hard corona and a dynamic soft corona, which subsequently influences their cellular recognition, endocytic pathways, and biodistribution in vivo.103 The protein corona can partially shield the targeting ligands on the nanoparticle surface, thus decreasing their accessibility to cell membrane receptors and attenuating specific cellular uptake.104 Furthermore, variations in nanoparticle physicochemical properties may lead to differences in the abundance of adsorbed proteins and protein corona composition, thereby influencing downstream biological effects.105 For instance, the protein corona formed by lipid nanoparticles (LNPs) is abundant in apolipoprotein E, which facilitates receptor-mediated uptake through lipoprotein receptors, particularly in the liver.106 Importantly, by modifying the lipid composition of LNPs, the composition of the protein corona can be altered, hence affecting its selectivity for particular organs,107 which may provide a potential strategy for improving cardiac targeting. Without the modification of protein repulsion coating, the surface chemical properties of inorganic nanoparticles make them more likely to adsorb immunoglobulins, complement, and fibrinogen.108 These proteins can accelerate the immune clearance of nanoparticles through complement activation and Fc receptor-mediated phagocytosis,109 thereby limiting targeted delivery efficiency. Moreover, biomimetic nanoparticles may inhibit non-specific protein adsorption, reduce the shielding effect of the protein corona on surface-targeting ligands, and preserve the recognition capability of these ligands toward target cell receptors.110 Therefore, rational engineering of nanoparticle properties and modulation of protein corona formation may improve the efficiency of cardiac targeting delivery. Systemic clearance is a critical factor influencing the delivery efficacy of nanoparticles. Premature clearance may reduce circulation time and limit nanoparticle accumulation in the myocardium.30 After systemic administration, nanoparticles are mainly cleared from the blood circulation by the mononuclear phagocyte system (MPS), particularly by Kupffer cells in the liver and macrophages in the spleen, which recognize opsonins, such as immunoglobulins and complement proteins adsorbed on the surface of the nanoparticles, and remove them through phagocytosis.111 It is worth noting that liver sinusoidal endothelial cells (LSECs) also play a significant role in the hepatic clearance of nanoparticles. The fenestrations of LSECs have a size-selective filtering function, limiting the trans-sinusoidal passage of nanoparticles larger than approximately 100 nm. The retained particles are subsequently cleared through endocytosis mediated by scavenger receptors, including Stabilin-1, Stabilin-2, and mannose receptors.112,113 Furthermore, glomerular filtration represents an additional size-dependent clearance pathway, as nanoparticles with hydrodynamic diameters below approximately 5.5 nm can traverse the glomerular filtration barrier and subsequently undergo urinary excretion.114 Overall, The clearance process of nanoparticles is mainly determined by their physicochemical properties, including particle size, surface charges, and surface chemical characteristics.30 Generally speaking, nanoparticles with larger particle size and positively charged surfaces are more likely to adsorb plasma proteins and undergo opsonization, thereby facilitating MPS-mediated recognition and phagocytic clearance.115 In contrast, neutral, hydrophilic, or protein-adsorption-resistant surface modifications can reduce the formation of non-specific protein corona, minimize immune system recognition, and prolong circulation time.116,117 Premature clearance reduces circulation time and limits cardiac accumulation, whereas insufficient clearance of nanoparticles may lead to prolonged tissue accumulation and potential toxicity. Therefore, balancing prolonged systemic circulation with safe and efficient clearance represents a key challenge for advancing nanoparticle-based therapies toward clinical translation. To overcome these barriers, nanoparticle-based systems have been designed using several complementary strategies, including material platform selection, targeted functionalization, and stimuli-responsive release strategies, which will be discussed in the following sections. Figure 4 showed the design strategies of nanoparticles in pathological cardiac hypertrophy, including the classifications of nanoparticle platforms, targeting strategies, and stimuli-responsive release strategies. Nanoparticle Platforms Based on the material composition and characteristics, nanoparticles for the treatment of pathological cardiac hypertrophy can be broadly divided into inorganic nanoparticles, organic nanoparticles, and biomimetic nanoparticles44,45,118 (Figure 4B). Table 1 provides a comparison among these three categories of nanoparticle platforms, summarizing their respective advantages, limitations, and main pharmacokinetic and biodistribution characteristics. Table 1Comparison of Different Nanoparticle Platforms for the Treatment of Pathological Cardiac HypertrophyCategoryRepresentative SystemsKey AdvantagesKey LimitationsMain Pharmacokinetic and Biodistribution CharacteristicsReferencesInorganic nanomaterialsGold nanoparticlesAnti-inflammatory and antioxidant activities, high specific surface areaLong-term accumulation, dose-dependent cytotoxicityLong systemic retention, accumulation in liver, spleen, and kidneys[119–131]Mesoporous silica nanoparticlesHigh specific surface area, tunable pore structureLong-term accumulation, potential immunotoxicityLimited biodegradation, accumulation in liver and spleen with prolonged tissue retention[132–135]Iron oxide nanoparticlesFavorable biocompatibility and biodegradability, magnetic targeting and imaging capabilitiesPotential induction of oxidative stress and cytotoxicityIron metabolism-associated degradation, accumulation in liver and spleen[136–140]Carbon-based nanoparticlesHigh specific surface area, superior mechanical strength, electrical conductivity, and scaffold propertiesLong-term accumulation, potential cytotoxicityLimited biodegradation, prolonged tissue retention[141–148]Organic nanomaterialsLiposomesExcellent biocompatibility and biodegradabilityManufacturing complexityLipid metabolism-associated clearance, liver and spleen distribution[149–158]Solid lipid nanoparticlesHigh biocompatibility, improved stabilityDrug expulsion during storageControlled release, prolonged systemic exposure[159–166]Polymeric nanoparticlesExcellent biocompatibility, high drug-loading capacityInitial burst release in some formulationsTunable degradation, controlled drug release, modifiable circulation and tissue distribution[167–172]Biomimetic nanomaterialsExtracellular vesiclesNative biocompatibility, intrinsic targeting ability, low immunogenicityLow production yield, lack of standardized production processesEndogenous membrane-mediated stability, source-dependent biodistribution and cellular uptake[173–177]Cell membrane-coated nanoparticlesImmune evasion, prolonged circulation, intrinsic targeting abilityComplex preparation processReduced immune recognition, prolonged systemic circulation, source-dependent biodistribution[178–182] Table 1Comparison of Different Nanoparticle Platforms for the Treatment of Pathological Cardiac HypertrophyCategoryRepresentative SystemsKey AdvantagesKey LimitationsMain Pharmacokinetic and Biodistribution CharacteristicsReferencesInorganic nanomaterialsGold nanoparticlesAnti-inflammatory and antioxidant activities, high specific surface areaLong-term accumulation, dose-dependent cytotoxicityLong systemic retention, accumulation in liver, spleen, and kidneys[119–131]Mesoporous silica nanoparticlesHigh specific surface area, tunable pore structureLong-term accumulation, potential immunotoxicityLimited biodegradation, accumulation in liver and spleen with prolonged tissue retention[132–135]Iron oxide nanoparticlesFavorable biocompatibility and biodegradability, magnetic targeting and imaging capabilitiesPotential induction of oxidative stress and cytotoxicityIron metabolism-associated degradation, accumulation in liver and spleen[136–140]Carbon-based nanoparticlesHigh specific surface area, superior mechanical strength, electrical conductivity, and scaffold propertiesLong-term accumulation, potential cytotoxicityLimited biodegradation, prolonged tissue retention[141–148]Organic nanomaterialsLiposomesExcellent biocompatibility and biodegradabilityManufacturing complexityLipid metabolism-associated clearance, liver and spleen distribution[149–158]Solid lipid nanoparticlesHigh biocompatibility, improved stabilityDrug expulsion during storageControlled release, prolonged systemic exposure[159–166]Polymeric nanoparticlesExcellent biocompatibility, high drug-loading capacityInitial burst release in some formulationsTunable degradation, controlled drug release, modifiable circulation and tissue distribution[167–172]Biomimetic nanomaterialsExtracellular vesiclesNative biocompatibility, intrinsic targeting ability, low immunogenicityLow production yield, lack of standardized production processesEndogenous membrane-mediated stability, source-dependent biodistribution and cellular uptake[173–177]Cell membrane-coated nanoparticlesImmune evasion, prolonged circulation, intrinsic targeting abilityComplex preparation processReduced immune recognition, prolonged systemic circulation, source-dependent biodistribution[178–182] Comparison of Different Nanoparticle Platforms for the Treatment of Pathological Cardiac Hypertrophy Inorganic Nanoparticles Inorganic nanoparticles are inorganic elemental nanomaterials, including metals, metal oxides, and silica, which have been widely used in the diagnosis and treatment of cardiac hypertrophy. Gold nanoparticles (AuNPs) have been reported to have anti-inflammatory and antioxidant properties that help to alleviate cardiac hypertrophy.119 It was found that 45 nm AuNPs could inhibit M1-associated pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukin-6, and induce M2-associated anti-inflammatory mediators, such as interleukin-10.120 AuNPs also exhibit enzyme-like activity, such as the activities of peroxidase,121 superoxide dismutase,122 and catalase.123 Owing to their high specific surface area,124 AuNPs can be used as excellent drug carriers for various therapeutic agents, including nucleic acids and small-molecule medicines.125,126 However, their inherent inertness to biodegradation and physicochemical stability may lead to long-term accumulation.127,128 AuNPs have been shown to accumulate in organs such as the liver, spleen, and kidneys over prolonged periods.129 Long-term accumulation may raise concerns for delayed toxicity. Nonetheless, the long-term safety of AuNPs remains unclear due to the limited availability of long-term in vivo studies.130 Moreover, the dose-dependent cytotoxicity cannot be ignored.131 Mesoporous silica nanoparticles (MSNs) exhibit excellent performance in the delivery of small molecules, siRNA, and proteins owing to their high specific surface area and tunable pore structures.132 Nevertheless, the porous structure facilitates the formation of protein corona, which may stimulate the proliferation of immune cells and abnormal inflammatory responses.133,134 Moreover, MSNs are susceptible to recognition by the mononuclear phagocytic system, which leads to their preferential enrichment in clearance organs such as the liver and spleen and long-term tissue retention.135 These biodistribution features could be related to long-term biosafety issues, as sustained exposure to silica-based materials could increase the risk for chronic inflammatory responses.135 Iron oxide nanoparticles (IONs) have several advantages, including excellent biocompatibility, biodegradability, and controllability by an external magnetic field.136 IONs are biodegradable and can be slowly degraded in vivo, and the released iron ions can be subsequently regulated by the endogenous iron homeostasis systems.137 However, after systemic administration, IONs may still be taken up by the mononuclear phagocyte system and accumulate preferentially in the clearance organs, especially the liver and spleen. Such biodistribution properties might restrict the availability of IONs in cardiac tissues and create a potential barrier to an efficient myocardial delivery.137 To this end, the application of an external magnetic field has been studied in an effort to achieve cardiac targeting. In an isoproterenol-induced cardiac hypertrophy, superparamagnetic IONs-labeled mesenchymal stem cells exhibited a significant improvement in cardiac homing ability in the presence of an external magnetic field.138 Nevertheless, the biosafety of IONs is still an important issue for further application. In another study, superparamagnetic iron oxide nanoparticles induced oxidative stress and ferroptosis at 50 ug/mL after 24 h in H9C2 cells,139 suggesting the cardiotoxic potential of IONs. Moreover, the long-term toxicity of IONs such as oxidative stress, DNA damage, inflammation, and metabolic dysregulation138 cannot be ignored.140 Carbon-based nanoparticles such as carbon nanotubes and graphene derivatives have attracted considerable attention owing to their high specific surface area, excellent mechanical strength, superior electrical properties, and tunable surface chemical properties.141–143 Furthermore, carbon-based nanoparticles have better reparative properties as scaffold materials in cardiac tissue engineering.144 Wang et al prepared fluorescent carbonized polymer dots by sulfur doping. This material can strongly prevent isoproterenol-induced cardiac hypertrophy and myocardial fibrosis by regulating mitochondrial function and reducing oxidative stress.145 However, their application is limited due to the possible cytotoxicity and biological persistence.146,147 Compared to biodegradable nanomaterials, many carbon-based nanoparticles exhibit limited biodegradability due to their stable carbon frameworks, which may contribute to slow clearance and prolonged retention in tissues.148 For example, intratracheal instillation of CBNPs at 50 μg per mouse once a week for 13 weeks resulted in accumulation of CBNPs in cardiac tissue, resulting in structural damage of mitochondria and activation of inflammatory and apoptotic pathways, resulting in myocardial injury.147 Overall, inorganic nanoparticles hold great promise for diagnostics and therapeutics. However, problems with biodegradability and long-term safety have limited their use.183 Organic Nanoparticles Compared with inorganic nanoparticles, organic nanoparticles exhibit good biocompatibility, degradability, and relatively low risks of long-term toxicity. Organic nanoparticles are mostly constituted of lipids and polymers, including liposomes, solid lipid nanoparticles (SLNs), and polymeric nanoparticles, largely approved by the Food and Drug Administration (FDA).184 Liposomes are spherical vesicles consisting of one or multiple phospholipid bilayers, and they are characterized by innate biocompatibility and degradability.149 Following systemic administration, liposomes are commonly taken up by the mononuclear phagocyte system and distributed to the liver and spleen. Owing to their biomimetic phospholipid composition, liposomes undergo lipid metabolism and clearance in vivo.150 The size and lamellarity of liposomes can be regulated to optimize in vivo circulation time, biodistribution, cellular absorption, and drug release patterns.151–153 Liposomes can be used to deliver therapeutic nucleic acids,154 peptides,155 and small molecule drugs156 in the treatment of cardiac hypertrophy. However, the preparation of liposomes typically involves multiple processing steps, and subtle variations in process parameters across these steps may accumulate into substantial batch-to-batch variability during scale-up production.157,158 Batch-to-batch variability is primarily reflected in changes in critical quality attributes, including particle size, polydispersity index, zeta potential, encapsulation efficiency, and drug release behavior, which may further affect the in vivo pharmacokinetic profiles and therapeutic efficacy of liposomes.36 SLNs are composed of a solid lipid core and a surfactant coating.159 In addition to their superior biocompatibility and biodegradability, SLNs exhibit high physical stability and provide controlled drug release,160,161 which may prolong systemic exposure of encapsulated drugs and improve their pharmacokinetic profiles. They are suitable for encapsulating hydrophobic or labile pharmaceuticals, as they increase the solubility of the active ingredient and also protect the payload from degradation, thus enhancing bioavailability.162–164 Zhu et al have reported that thiopental sodium-loaded SLNs may reduce the cardiac hypertrophy induced by obesity significantly through inhibition of the p38 MAPK-mediated inflammatory pathway.165 SLNs have excellent physical stability, but during storage, they suffer from lipid polymorphic transitions, which can result in drug expulsion and reduction of long-term storage stability.166 Polymeric nanoparticles are prepared from natural or synthetic polymers and show good biocompatibility and biodegradability.167 Polymeric nanoparticles can be prepared by self-assembly, emulsion polymerization, or nanoprecipitation techniques.168 Biodegradable polymers, such as poly (lactic-co-glycolic acid) (PLGA), can gradually degrade in vivo, and their degradation rate may influence drug release kinetics and systemic exposure.169 Owing to their substantial loading capacity, polymeric nanoparticles may effectively transport diverse bioactive molecules, such as nucleic acids and small-molecule medicines, and have therefore been extensively utilized in the treatment of cardiac hypertrophy.170,171 Nevertheless, polymeric nanoparticles face obstacles such as complex preparation processes and an initial burst release in some formulations.172 In summary, organic nanoparticles possess considerable benefits for safety and biodegradability, rendering them appropriate for chronic cardiovascular conditions such as cardiac hypertrophy. Biomimetic Nanoparticles Biomimetic nanoparticles have been developed rapidly in recent years. They are hybrid delivery systems, which are produced by combining functional nanomaterials with biological materials obtained from natural sources such as extracellular vesicles (EVs) and cell membranes.185 The biomimetic nanoparticles have many merits, including long circulation time, immune escape, intrinsic targeting, and biological compatibility.186–188 Extracellular vesicles (EVs) are membrane vesicles, such as exosomes, microvesicles, and apoptotic bodies, with lipid bilayer structures. These vesicles have intrinsic loading capacities and are therefore suitable carriers for therapeutic agents such as miRNAs and small interfering RNAs.173,174 The different compositions of the membranes result in different fates of EVs in the body, such as their stability, cellular uptake, degradation, and tissue distribution. These factors collectively influence their pharmacokinetic behavior and biological distribution.175 However, low production yield and the absence of standardized production processes have limited their clinical translation.176 Additionally, variations in source cells, culture conditions, and isolation methods can alter EV composition, cargo profiles, and biological activity, leading to batch-to-batch inconsistency.177 Another important class of biomimetic nanoparticles is cell membrane-coated nanoparticles. The cores of the nanoparticles were coated with membranes of erythrocytes,178 platelets,22 macrophages,179 or neutrophils.24 These biomimetic nanoparticles preserve the structure of the lipid bilayer and membrane-associated proteins and retain the physicochemical properties of the nanoparticle cores. This structure enables them to evade immune recognition and prolong circulation time in the body. Furthermore, the specific membrane proteins from different cell types determine their interactions with tissues and ultimately establish their biodistribution characteristics.180 Recently, cell membrane-coated nanoparticles have drawn much attention for cardiac hypertrophy treatment. For instance, Li et al explored the co-assembly of platelet and erythrocyte membranes into JQ1-loaded nanoparticles. The nanosystem showed longer circulation time and enhanced cardiac targeting ability compared to free JQ1.22 However, the preparation procedure of cell membrane-coated nanoparticles is rather complicated. It involves multiple steps, including cell membrane extraction and purification, nanocore preparation, and membrane encapsulation.181 Furthermore, difficulties in maintaining consistent membrane composition, coating efficiency, and protein preservation may lead to batch-to-batch variations.182 Targeting Strategies Targeting strategies are important factors that influence the therapeutic efficacy of nanoparticles. Currently, targeting strategies mainly include passive targeting, active targeting, and biomimetic targeting (Figure 4C). Passive Targeting Passive targeting refers to the distribution and tissue accumulation of nanoparticles independent of specific targeting ligands. These processes are influenced by the physiological and pathological conditions of the body, as well as the physicochemical properties of nanoparticles. Chronic pressure overload and neurohumoral activation may lead to endothelial dysfunction and microvascular remodeling in cardiac hypertrophy.189 These pathological changes increase vascular permeability and promote the extravasation of nanoparticles into the myocardial tissue. However, due to the lack of the typical EPR effect, the enhanced vascular permeability does not lead to sufficient accumulation of nanoparticles in the myocardial tissue.98 In the following part, we will focus on the influence of the physicochemical properties of nanoparticles on the passive targeting. Nanoparticle size is a critical determinant of their circulation behavior, clearance pathways, and tissue exposure. Nanoparticles smaller than 5.5 nm can be rapidly cleared by the kidneys.114 Nanoparticles larger than 200 nm tend to be taken up and cleared by the MPS.190 While an appropriate particle size may prolong the circulation time and enhance the likelihood of nanoparticle accumulation in hypertrophic myocardium, the myocardial accumulation is also affected by material composition, surface properties, protein corona formation, and interactions with the biological environment.30 Therefore, particle size should not be considered as the sole determinant of passive targeting. Surface charge is another important factor affecting passive targeting. Under normal physiological conditions, the outer membranes of most cells, including cardiomyocytes, carry a net negative charge.191,192 Nanoparticles with a positive charge are more likely to be taken up by negatively charged target cells, but they are also more easily rapidly taken up and cleared by MPS.193 Negatively charged or neutral nanoparticles are less susceptible to MPS-mediated clearance but often exhibit reduced uptake by target cells. Charge-reversal carriers seem to be a highly promising solution to address this problem. Charge-reversal carriers maintain a neutral or negative charge in the bloodstream to prolong circulation time and turn to a positive charge at the target site to enhance cell uptake.194 However, at present, the application of such strategies in pathological cardiac hypertrophy is still rather limited, and its development is constrained by factors such as the heterogeneity of the myocardial pathological microenvironment and the controllability of triggering conditions. Moreover, the shape of nanoparticles considerably influences their duration in circulation and their engagement with cells. Spherical nanoparticles are rapidly cleared by the MPS, resulting in a shorter circulation time. In contrast, non-spherical nanostructures (such as rods, filaments, and elliptical discs) exhibit pronounced flow-induced orientational alignment under shear flow. This behavior is primarily governed by rotational dynamics, which can prolong their circulation time by reducing the effective surface area exposed to macrophage recognition and uptake.195,196 Meanwhile, in the region close to the vessel wall, the translational dynamics triggered by the collision with red blood cells promote their migration to the vascular endothelium. Non-spherical particles can further enhance their adhesion stability after reaching the vessel wall by increasing contact area with the endothelium,197 promoting their adhesion and penetration in hypertrophic myocardial regions. These shape-dependent advantages may increase the exposure level of nanoparticles in hypertrophic myocardium. However, whether such advantages can further promote the selective accumulation of nanoparticles in hypertrophic myocardium still lacks sufficient validation. The tissue selectivity of passive targeting is inherently limited, as it depends on nonspecific accumulation driven by pathophysiological changes rather than active recognition of cardiac‑specific targets. Thus, passive targeting should be considered primarily as a supplementary strategy to enhance drug delivery, rather than a standalone modality for precision cardiac targeting. Active Targeting Active targeting refers to a delivery strategy associated with the surface modification of nanoparticles with specific ligands, peptides, or antibodies. Therapeutic agents are precisely delivered to specific cell populations within hypertrophic myocardial tissue through the ligand-receptor interaction, thereby enhancing the efficiency of drug delivery.198 Cardiomyocytes are the primary therapeutic targets for interventions aimed at regulating hypertrophy signaling, metabolic reprogramming, and transcriptional dysregulation. Cardiomyocyte membranes express a variety of specific receptors, including β-adrenergic receptors, angiotensin II type 1 receptors, and natriuretic peptide receptors.199,200 By conjugating appropriate ligands, peptides, or antibodies to nanoparticles, specific recognition of receptors can be achieved, promoting receptor-mediated cellular uptake and thereby enhancing the accumulation efficiency of nanoparticles within cardiomyocytes.201,202 In recent years, targeted peptides derived from phage display technology (such as cardiac-targeting peptides and cardiac homing peptides) have also shown potential as ligands for targeting cardiomyocytes.203–205 In addition to cardiomyocytes, endothelial cells represent another important therapeutic target in pathological cardiac hypertrophy. In hypertrophic myocardium, endothelial cells have elevated surface expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin.206–208 Nanoparticles functionalized with antibodies or peptides against these markers can improve vascular adhesion and retention, facilitating delivery across the endothelium into the cardiac tissue.209 Cardiac fibroblasts are the main contributors to myocardial fibrosis.210 Myocardial fibrosis can be alleviated by delivering anti-fibrotic agents to activated fibroblasts by modifying the surface of nanoparticles with targeted ligands targeting fibroblast-related markers such as fibroblast activation protein,211 platelet-derived growth factor receptor alpha,212 and integrins.213 Immune cells, especially macrophages, play a crucial role in inflammatory response and fibroblast activation.214 Ligand-functionalized nanoparticles targeting macrophage-associated markers such as mannose receptors, integrins, and scavenger receptors215,216 can promote selective delivery of therapeutic cargos to macrophages and enable regulation of inflammatory responses. Biomimetic Targeting Biomimetic targeting is an emerging strategy. Compared with passive and active targeting, biomimetic targeting takes advantage of the synergistic effects of various natural surface molecules, improving the targeting ability of nanoparticles in hypertrophic myocardium. For instance, naturally occurring extracellular vesicles from stem cells, immune cells, and cardiomyocytes are preferentially accumulated in injured cardiac tissues.217–221 Platelet membrane-coated nanoparticles can preferentially adhere to damaged endothelial cells and sites of inflammation.222 Macrophage membrane-coated nanoparticles actively target inflammatory sites.223,224 Such multivalent molecular interactions are especially useful for the complex and changing pathological microenvironment of cardiac hypertrophy. Stimuli-Responsive Release in Cardiac Hypertrophy Stimuli-responsive release enables spatiotemporally controlled drug release.225 The pathological microenvironment of cardiac hypertrophy is characterized by increased levels of ROS,226 enhanced acidosis,227 and increased activity of matrix-remodeling enzymes,228,229 which can be used to trigger drug release at specific sites (Figure 4D). Engineered nanoparticles with cleavable bonds or stimuli-sensitive structures can respond to these pathological signals. These systems remain stable in the systemic circulation and release therapeutic cargos at the lesion site, thereby improving local drug bioavailability and reducing systemic exposure.230 Reactive Oxygen Species (ROS)‑Responsive Release ROS-responsive nanoparticles are constructed by integrating ROS-cleavable moieties such as phenylboronic esters,231 thioethers,232 thioketals,233 and diselenide bonds234 into the nanomaterials. These moieties remain stable under physiological conditions but are cleaved in ROS-rich microenvironments, resulting in site-specific release of the loaded drugs. In the study by Chen et al, ROS-responsive nanomicelles loaded with celastrol were constructed for the treatment of pressure overload-induced cardiac hypertrophy. It has been demonstrated that the drug release rate was only 19.4% in the absence of H2O2, while in the presence of 1 mM H2O2, the release rate increased to 71.5% within 48 h.235 pH‑Responsive Release pH-responsive nanoparticles usually achieve drug-responsive release by introducing acid-labile chemical bonds, such as hydrazone bonds236 and Schiff bases,237 or using pH-sensitive polymers.238 A study in the context of myocardial infarction has demonstrated the feasibility of pH-sensitive systems for cardiac repair,238 suggesting their potential translatability to cardiac hypertrophy. However, the application of pH-responsive nanoparticles in cardiac hypertrophy is still limited. Enzyme‑Responsive Release The extracellular matrix undergoes pathological remodeling in cardiac hypertrophy, and the expression levels and activities of proteases such as MMP-2 and MMP-9 are markedly elevated.239,240 These enzymes are involved in the decomposition of collagen241 and the activation of certain cytokines.242 Meanwhile, MMPs can also serve as endogenous triggers for the release of therapeutic agents from biomaterials. A study designed MMP-2/9 activatable peptide probes to achieve specific imaging of MMP activity at the cardiac remodeling sites after ischemia. The probe was constructed by linking polyanionic peptides and polycationic peptides with MMP-sensitive peptides. At pathological sites with high MMP-2/9 activity, the substrate was cleaved, and the polycationic peptide carrying a radioactive signal remained in the tissue, while the polyanionic peptide carrying another radioactive signal was cleared. By calculating the ratio of the two radioactive signals, the activity of MMP-2/9 could be evaluated.243 Beyond imaging applications, MMP-responsive systems have also been investigated for the treatment of tumors244,245 and rheumatoid arthritis,246 demonstrating the feasibility of utilizing elevated MMP activity for controlled cargo release. However, research on the application of MMP-responsive systems in cardiac hypertrophy remains very limited. It remains unclear whether the magnitude and spatial distribution of MMP activity in hypertrophic myocardium are sufficient to trigger effective drug release from the nanoparticles. Moreover, the therapeutic efficacy, activation specificity, and translational feasibility require further validation in relevant hypertrophic models. Administration Routes Finally, the routes of administration are also important considerations. The main routes of administration are intravenous, intraperitoneal, intradermal, inhalation, and oral administration (Figure 4E). The most commonly used route for nanoparticles is intravenous administration, which ensures absolute bioavailability.247 This route is compatible with various nanocarrier platforms, including liposomes, polymeric nanoparticles, and biomimetic nanoparticles.248 However, long-term repeated injections pose an increased risk of infection and vascular irritation and a drastic decrease in patient compliance, highlighting the urgent need for alternatives.249 Intraperitoneal injection has been widely used to deliver nanoparticles in rodent models due to the procedural simplicity and suitability for repeated administration.250 Nanoparticles are taken up by the peritoneal capillary network and the lymphatic system to reach the systemic circulation, thus leading to more complex pharmacokinetic profiles.251 Furthermore, intraperitoneal injection is intrinsically associated with the risk of peritonitis, irritation of visceral organs, and mechanical damage to tissues.252 Intradermal injection is a less invasive route that facilitates uptake of the nanoparticles by the dermal immune cells. The high density of antigen-presenting cells such as dendritic cells (DCs) in the dermis provides a unique opportunity for immunomodulatory therapy.253 Kwon et al demonstrated that DCs internalized lipid nanoparticles co-loaded with myocardial infarction-associated antigens and rapamycin, which elicited antigen-specific regulatory T cell (Treg) responses leading to decreased inflammation, attenuated ventricular remodeling, and improved cardiac function after myocardial infarction.254 However, intradermal injection has not been extensively studied in pathological cardiac hypertrophy, and its therapeutic potential needs to be further validated. Inhalation administration is a non-invasive route that exploits the large surface area and dense network of alveolar capillaries to enhance nanoparticle transport to the systemic circulation.255 Inhalation administration has several advantages, such as ease of administration, suitability for repeated dosing, and possibly improved patient compliance. However, the clinical translation of inhalation therapies is still hampered by challenges in delivery device compatibility, accurate dose control, pulmonary immune responses, and long-term safety assessment.256 Oral administration is an attractive strategy for long-term management of chronic cardiovascular diseases due to its noninvasiveness and high patient acceptability.257 However, the oral route is burdened with several challenges such as gastric acid, enzymatic degradation, mucus obstruction, and post-absorptive intestinal and hepatic processing, which all together affect the stability, systemic exposure, and bioavailability of the nanoparticles.258 Alhusaini et al reported that oral administration of resveratrol-loaded liposomes improved cardiac remodeling in isoproterenol-induced rats, indicating the potential of oral nanoparticle-based strategies in modulating pathological cardiac remodeling.259 However, oral nanotherapy for pathological cardiac hypertrophy is still in the early stage, and its cardiac delivery efficiency and long-term safety need to be validated. Collectively, the selection of administration routes requires a balance between therapeutic efficacy, safety, and translational feasibility. Despite encouraging preclinical advances, clinically applicable delivery strategies for pathological cardiac hypertrophy remain to be established. The Preclinical Applications of Nanoparticles in the Treatment of Cardiac Hypertrophy Recently, nanoparticle-based therapies have emerged as a promising approach for the treatment of pathological cardiac hypertrophy due to their ability to enhance targeted delivery of therapeutic agents, optimize pharmacokinetic properties, and improve drug accumulation in cardiac tissue.22–25 This section summarizes recent preclinical studies of nanoparticle-based treatments for pathological cardiac hypertrophy, including gene and epigenetic regulation, anti-oxidative, anti-inflammatory, and anti-fibrotic therapies. A thorough literature search was performed in the PubMed and Web of Science databases up to February 2026. The search strategy integrated controlled vocabulary and free-text keywords pertinent to cardiac hypertrophy and nanoparticle therapy, encompassing “cardiac hypertrophy”, “nanoparticles”, “gene therapy”, “epigenetic regulation”, “anti-inflammatory”, “anti-fibrotic”, and “antioxidant”, employing Boolean operators (AND/OR). Only articles published in peer-reviewed journals were considered. Further relevant studies were identified by reverse citation analysis of the reference lists of the listed articles. Table 2 provides a comprehensive summary of representative preclinical studies employing nanoparticle-based strategies for the treatment of pathological cardiac hypertrophy, highlighting key parameters including nanoparticle platforms, targeting strategies, therapeutic payloads, administration routes, animal models, and major functional outcomes. It is necessary to emphasize that there is a significant heterogeneity among different animal models of pathological cardiac hypertrophy. Neurohumoral stress models, including those induced by isoproterenol (ISO)13 or angiotensin II (Ang II),174 are employed to study cardiac remodeling associated with sympathetic overactivation or renin-angiotensin-aldosterone system (RAAS) dysregulation, respectively. Pressure overload models, including transverse aortic constriction (TAC)260 and abdominal aorta constriction67 induced models, recapitulate key features of pathological hypertrophy associated with hypertension and aortic stenosis. Myocardial infarction models established by left anterior descending artery ligation are used to investigate post-ischemic cardiac remodeling following coronary artery disease.81 Further, cardiac hypertrophy induced by diabetes125 and monocrotaline-induced right ventricular hypertrophy250 are distinct pathological contexts, namely diabetic cardiomyopathy and right ventricular remodeling due to pulmonary arterial hypertension, respectively. These animal models show significant differences in the molecular mechanisms of cardiac remodeling, including the major activated signaling pathways, inflammatory responses, metabolic alterations, and fibrosis.1,12 The heterogeneity of the models must therefore be carefully taken into account when evaluating the therapeutic efficacy of different nanoparticle-based treatments. In addition to the heterogeneity of animal models, preclinical studies are characterized by a large variation in terms of nanoparticle materials, loaded agents, administration routes, dosing schedules, and criteria for efficacy assessment. The therapeutic efficacy obtained with different nanoparticle-based approaches should be taken with caution, as the difference in efficacy may depend on several experimental parameters. Table 2Preclinical Studies of Nanoparticle-Based Therapies for Pathological Cardiac HypertrophyMaterial PlatformsTargeting StrategiesLoaded AgentSizeAdministration RouteAnimal ModelFunctional OutcomesEffectsReferencesNanoparticle-based gene and epigenetic therapiesErythrocyte membrane-coated NPsActive targeting via TAT and PCM and biomimetic targetingSecretoneurin plasmid DNA<350 nmIntravenous injectionC57BL/6 mice induced by ISOIncreased EF and FS, decreased LV massEnhance the expression of Secretoneurin[23]Milk-derived extracellular vesiclesActive targeting via IMTPmiR30d142 nmIntravenous injectionC57BL/6 mice induced by TAC, Ang II, and ISOIncreased EF, FS, decreased LVEDV and LVESVDownregulate the expression of GRK5[198]Polymeric NPsPassive targetingmiR182 inhibitor150-250 nmIntravenous injectionC57BL/6 mice induced by TACIncreased EF, FS, decreased LV massRestore the expression of FOXO3[260]Gold NPsPassive targetingmiR155 antagonist20-40 nmIntravenous injectionC57BL/6 mice subjected to ovariectomy and streptozotocin treatmentIncreased EF, FSPromote M2 macrophage polarisation and decrease cardiac apoptosis, cardiac hypertrophy, and fibrosis[125]Extracellular vesiclesActive targeting via CTPNOX4 siRNA139 nmIntravenous injectionC57BL/6 mice induced by Ang IIIncreased EF, FSReduce NOX4 expression and oxidative stress[174]Neutrophil membrane-coated MSNsBiomimetic targetingsiRNA of LncRNA AAB110 nmIntravenous injectionWistar rats induced by abdominal aorta constrictionIncreased EF, FSSilence lncRNA AAB, restore miR-30b-5p, and inhibit ferroptosis[67]Platelet and erythrocyte membrane-coated NPsBiomimetic targetingJQ1183-195 nmIntravenous injectionC57BL/6 mice induced by TAC and permanent ligation of the LADIncreased EF, FSInhibit bromodomain and extraterminal domain (BET) proteins[22]Nanoparticle-mediated anti-oxidative therapiesPolymeric NPsPassive targetingTannic acid79±2 nmIntravenous injectionC57BL/6 mice induced by ISOIncreased EFScavenge reactive oxygen species[261]Cur NPsPassive targetingCurcumin50-100 nmIntraperitoneal injectionSprague Dawley rats induced by monocrotalineDecreased RV AVFWScavenge reactive oxygen species and inflammatory factors[250]PB-CurPassive targetingCurcumin30 nmIntravenous injectionC57BL/6 mice induced by TACIncreased EF, FS, decreased LV massScavenge reactive oxygen and nitrogen species[262]MnO2 NPsPassive targetingEpigallocatechin gallate350 nmIntraperitoneal injectionSprague-Dawley rats induced by monocrotalineDecreased RVHIScavenge reactive oxygen and nitrogen species[263]LiposomesActive targeting via homing peptideSuperoxide dismutase and fasudil150 nmIntratracheal administrationSprague-Dawley rats induced by monocrotalineDecreased RVHIScavenge reactive oxygen species, inhibit vascular remodeling[264]Polymeric NPsPassive targetingDeath receptor 5 fusion protein202 ± 2 nmIntravenous injectionSprague-Dawley rats induced by ligation of the LADIncreased EF, FSScavenge reactive oxygen species, reduce apoptosis[81]sulfur-doped carbonized polymer dotsPassive targetingNone2.58 nmIntravenous injectionSprague-Dawley rats induced by ISOIncreased EF, FS, decreased LV massscavenge reactive oxygen species, restore mitochondrial function[145]Nanoparticle-mediated anti-inflammatory therapiesLiposomesPassive targetingResveratrol200 nmOral administrationWistar rats induced by ISONot reportedInhibit inflammation and apoptosis[259]LiposomesPassive targetingBerberine110 nmIntravenous injectionC57BL/6 mice induced by permanent ligation of the LADIncreased EF and FS, decreased LV massInhibit inflammation[265]Lipid core NPsPassive targetingMethotrexate60 nmIntraperitoneal injectionWistar rats induced by permanent ligation of left coronary arteryIncreased EF, decreased LV massIncrease adenosine bioavailability and upregulate vascular endothelial growth factor expression[266]LiposomesPassive targetingRapamycin and myocardial infarction antigens200 nmIntradermal injectionC57BL/6 mice induced by permanent ligation of the LADIncreased EF and FS, decreased LVESVInduce antigen-specific regulatory T cells and M2 macrophage polarization, attenuate excessive inflammation[254]PEG-coated gold NPsPassive targetingGold13, 30, and 50 nmIntravenous injectionFVB/N mice induced by ISODecreased LVPWd, no significant changes in EF and FSInhibit ERK1/2 phosphorylation[119]Neutrophil membrane-coated NPsBiomimetic targetingInterleukin-5120 nmIntravenous injectionC57BL/6 mice induced by ligation of the LADIncreased EF and FS, decreased LVESV and LVEDVPromote M2 macrophage polarization and reduce post-ischemic inflammation[24]Nanoparticle-mediated anti-fibrotic therapiesMacrophage membrane-coated PLGA-NPsBiomimetic targetingLutein228 nmIntravenous injectionC57BL/6 mice induced by TACIncreased EF and FS, decreased LVPWd and LVPWSInhibit IL-11/ERK signaling pathway, exert anti-fibrotic effects and avoid being engulfed by macrophages[179]Naturally self-assembled supramolecular NPsPassive targeting43 chemical components134 ± 7 nmIntraperitoneal injectionC57BL/6 mice induced by ISOIncreased EF and FS, decerased LVIDsInhibit collagen deposition and endothelial-to-mesenchymal transition[267]Extracellular vesiclesBiomimetic targetingGW788388 (TGF-β1 receptor inhibitor)150 nmIntravenous injectionC57BL/6 mice induced by ISOIncreased EF and FS, decreased LVIDd and LVIDsInhibit TGF-β1/Smad3 Signaling pathway[93]Lipid NPsActive targeting via anti-ICAM-1 antibodiesCholecystokinin octapeptide and oxygen335 nmIntravenous injectionSprague-Dawley rats induced by ligation of the LAD for 90minsIncreased EF and FSReduce inflammatory factors, decrease collagen deposition, and protect mitochondrial function[209]PLGA-NPsActive targeting via cardiac homing peptideMelatonin221 ± 13 nmIntravenous injectionSprague-Dawley rats induced by TACDecreased LVPWd and LVPWS, no significant changes in EF and FSDownregulate the TGF-β1/Smad3 signaling pathway and reduce collagen deposition[205]Calcium phosphate (CaP) NPsActive targeting via CTPTP-1085 nmIntratracheal inhalationC57BL/6J mice induced by TACIncreased EF and FS, decreased LVIDs and LVIDdInhibit cAMP/AMPK and cGMP/PKG signaling pathways[204]Abbreviations: NPs, nanoparticles; TAT, transactivating transcriptional activator peptide; PCM, peptide targeting cardiomyocytes; pDNA, plasmid DNA; ISO, isoproterenol; EF, ejection fraction; FS, fractional shortening; LV mass, left ventricular mass; IMTP, ischemic myocardium targeting peptide; Ang II, Angiotensin II; MSNs, mesoporous silica NPs; CTP, cardiac-targeting peptide; TAC, transverse aortic constriction; LAD, left anterior descending artery; RV AVFW, right ventricular anterior free wall thickness; RVHI, right ventricular hypertrophy index (RV/LV + S), the ratio of the right ventricular/left ventricular + septum weights; LVEDV, left ventricle end diastolic volume; LVESV, left ventricle end systolic volume; LVPWd, diastolic left ventricular posterior wall thickness; LVPWs, systolic left ventricular posterior wall thickness; LVIDs, left ventricular end systolic diameter; LVIDd, left ventricular end diastolic diameter; ICAM-1, intercellular adhesion molecule-1. Table 2Preclinical Studies of Nanoparticle-Based Therapies for Pathological Cardiac HypertrophyMaterial PlatformsTargeting StrategiesLoaded AgentSizeAdministration RouteAnimal ModelFunctional OutcomesEffectsReferencesNanoparticle-based gene and epigenetic therapiesErythrocyte membrane-coated NPsActive targeting via TAT and PCM and biomimetic targetingSecretoneurin plasmid DNA<350 nmIntravenous injectionC57BL/6 mice induced by ISOIncreased EF and FS, decreased LV massEnhance the expression of Secretoneurin[23]Milk-derived extracellular vesiclesActive targeting via IMTPmiR30d142 nmIntravenous injectionC57BL/6 mice induced by TAC, Ang II, and ISOIncreased EF, FS, decreased LVEDV and LVESVDownregulate the expression of GRK5[198]Polymeric NPsPassive targetingmiR182 inhibitor150-250 nmIntravenous injectionC57BL/6 mice induced by TACIncreased EF, FS, decreased LV massRestore the expression of FOXO3[260]Gold NPsPassive targetingmiR155 antagonist20-40 nmIntravenous injectionC57BL/6 mice subjected to ovariectomy and streptozotocin treatmentIncreased EF, FSPromote M2 macrophage polarisation and decrease cardiac apoptosis, cardiac hypertrophy, and fibrosis[125]Extracellular vesiclesActive targeting via CTPNOX4 siRNA139 nmIntravenous injectionC57BL/6 mice induced by Ang IIIncreased EF, FSReduce NOX4 expression and oxidative stress[174]Neutrophil membrane-coated MSNsBiomimetic targetingsiRNA of LncRNA AAB110 nmIntravenous injectionWistar rats induced by abdominal aorta constrictionIncreased EF, FSSilence lncRNA AAB, restore miR-30b-5p, and inhibit ferroptosis[67]Platelet and erythrocyte membrane-coated NPsBiomimetic targetingJQ1183-195 nmIntravenous injectionC57BL/6 mice induced by TAC and permanent ligation of the LADIncreased EF, FSInhibit bromodomain and extraterminal domain (BET) proteins[22]Nanoparticle-mediated anti-oxidative therapiesPolymeric NPsPassive targetingTannic acid79±2 nmIntravenous injectionC57BL/6 mice induced by ISOIncreased EFScavenge reactive oxygen species[261]Cur NPsPassive targetingCurcumin50-100 nmIntraperitoneal injectionSprague Dawley rats induced by monocrotalineDecreased RV AVFWScavenge reactive oxygen species and inflammatory factors[250]PB-CurPassive targetingCurcumin30 nmIntravenous injectionC57BL/6 mice induced by TACIncreased EF, FS, decreased LV massScavenge reactive oxygen and nitrogen species[262]MnO2 NPsPassive targetingEpigallocatechin gallate350 nmIntraperitoneal injectionSprague-Dawley rats induced by monocrotalineDecreased RVHIScavenge reactive oxygen and nitrogen species[263]LiposomesActive targeting via homing peptideSuperoxide dismutase and fasudil150 nmIntratracheal administrationSprague-Dawley rats induced by monocrotalineDecreased RVHIScavenge reactive oxygen species, inhibit vascular remodeling[264]Polymeric NPsPassive targetingDeath receptor 5 fusion protein202 ± 2 nmIntravenous injectionSprague-Dawley rats induced by ligation of the LADIncreased EF, FSScavenge reactive oxygen species, reduce apoptosis[81]sulfur-doped carbonized polymer dotsPassive targetingNone2.58 nmIntravenous injectionSprague-Dawley rats induced by ISOIncreased EF, FS, decreased LV massscavenge reactive oxygen species, restore mitochondrial function[145]Nanoparticle-mediated anti-inflammatory therapiesLiposomesPassive targetingResveratrol200 nmOral administrationWistar rats induced by ISONot reportedInhibit inflammation and apoptosis[259]LiposomesPassive targetingBerberine110 nmIntravenous injectionC57BL/6 mice induced by permanent ligation of the LADIncreased EF and FS, decreased LV massInhibit inflammation[265]Lipid core NPsPassive targetingMethotrexate60 nmIntraperitoneal injectionWistar rats induced by permanent ligation of left coronary arteryIncreased EF, decreased LV massIncrease adenosine bioavailability and upregulate vascular endothelial growth factor expression[266]LiposomesPassive targetingRapamycin and myocardial infarction antigens200 nmIntradermal injectionC57BL/6 mice induced by permanent ligation of the LADIncreased EF and FS, decreased LVESVInduce antigen-specific regulatory T cells and M2 macrophage polarization, attenuate excessive inflammation[254]PEG-coated gold NPsPassive targetingGold13, 30, and 50 nmIntravenous injectionFVB/N mice induced by ISODecreased LVPWd, no significant changes in EF and FSInhibit ERK1/2 phosphorylation[119]Neutrophil membrane-coated NPsBiomimetic targetingInterleukin-5120 nmIntravenous injectionC57BL/6 mice induced by ligation of the LADIncreased EF and FS, decreased LVESV and LVEDVPromote M2 macrophage polarization and reduce post-ischemic inflammation[24]Nanoparticle-mediated anti-fibrotic therapiesMacrophage membrane-coated PLGA-NPsBiomimetic targetingLutein228 nmIntravenous injectionC57BL/6 mice induced by TACIncreased EF and FS, decreased LVPWd and LVPWSInhibit IL-11/ERK signaling pathway, exert anti-fibrotic effects and avoid being engulfed by macrophages[179]Naturally self-assembled supramolecular NPsPassive targeting43 chemical components134 ± 7 nmIntraperitoneal injectionC57BL/6 mice induced by ISOIncreased EF and FS, decerased LVIDsInhibit collagen deposition and endothelial-to-mesenchymal transition[267]Extracellular vesiclesBiomimetic targetingGW788388 (TGF-β1 receptor inhibitor)150 nmIntravenous injectionC57BL/6 mice induced by ISOIncreased EF and FS, decreased LVIDd and LVIDsInhibit TGF-β1/Smad3 Signaling pathway[93]Lipid NPsActive targeting via anti-ICAM-1 antibodiesCholecystokinin octapeptide and oxygen335 nmIntravenous injectionSprague-Dawley rats induced by ligation of the LAD for 90minsIncreased EF and FSReduce inflammatory factors, decrease collagen deposition, and protect mitochondrial function[209]PLGA-NPsActive targeting via cardiac homing peptideMelatonin221 ± 13 nmIntravenous injectionSprague-Dawley rats induced by TACDecreased LVPWd and LVPWS, no significant changes in EF and FSDownregulate the TGF-β1/Smad3 signaling pathway and reduce collagen deposition[205]Calcium phosphate (CaP) NPsActive targeting via CTPTP-1085 nmIntratracheal inhalationC57BL/6J mice induced by TACIncreased EF and FS, decreased LVIDs and LVIDdInhibit cAMP/AMPK and cGMP/PKG signaling pathways[204]Abbreviations: NPs, nanoparticles; TAT, transactivating transcriptional activator peptide; PCM, peptide targeting cardiomyocytes; pDNA, plasmid DNA; ISO, isoproterenol; EF, ejection fraction; FS, fractional shortening; LV mass, left ventricular mass; IMTP, ischemic myocardium targeting peptide; Ang II, Angiotensin II; MSNs, mesoporous silica NPs; CTP, cardiac-targeting peptide; TAC, transverse aortic constriction; LAD, left anterior descending artery; RV AVFW, right ventricular anterior free wall thickness; RVHI, right ventricular hypertrophy index (RV/LV + S), the ratio of the right ventricular/left ventricular + septum weights; LVEDV, left ventricle end diastolic volume; LVESV, left ventricle end systolic volume; LVPWd, diastolic left ventricular posterior wall thickness; LVPWs, systolic left ventricular posterior wall thickness; LVIDs, left ventricular end systolic diameter; LVIDd, left ventricular end diastolic diameter; ICAM-1, intercellular adhesion molecule-1. Preclinical Studies of Nanoparticle-Based Therapies for Pathological Cardiac Hypertrophy Abbreviations: NPs, nanoparticles; TAT, transactivating transcriptional activator peptide; PCM, peptide targeting cardiomyocytes; pDNA, plasmid DNA; ISO, isoproterenol; EF, ejection fraction; FS, fractional shortening; LV mass, left ventricular mass; IMTP, ischemic myocardium targeting peptide; Ang II, Angiotensin II; MSNs, mesoporous silica NPs; CTP, cardiac-targeting peptide; TAC, transverse aortic constriction; LAD, left anterior descending artery; RV AVFW, right ventricular anterior free wall thickness; RVHI, right ventricular hypertrophy index (RV/LV + S), the ratio of the right ventricular/left ventricular + septum weights; LVEDV, left ventricle end diastolic volume; LVESV, left ventricle end systolic volume; LVPWd, diastolic left ventricular posterior wall thickness; LVPWs, systolic left ventricular posterior wall thickness; LVIDs, left ventricular end systolic diameter; LVIDd, left ventricular end diastolic diameter; ICAM-1, intercellular adhesion molecule-1. Moreover, preclinical studies of nanoparticle-based therapies for pathological cardiac hypertrophy show a skewed distribution across different nanoparticle platforms. Organic nanoparticle platforms, such as liposomes and polymeric nanoparticles, have been the mainstay of preclinical work due to their relatively mature manufacturing processes, versatile drug delivery capabilities,268,269 and decades of extensive clinical translation experience.184 In contrast, biomimetic nanoparticle platforms are a rapidly developing category of nanocarriers that have garnered considerable attention recently.270 Despite their significant therapeutic potential,271 the existing preclinical evidence for biomimetic nanoparticles in pathological cardiac hypertrophy remains relatively insufficient compared with that for organic nanoparticles. Moreover, inorganic and carbon-based nanoparticles remain relatively less explored in cardiac hypertrophy therapy, resulting in a limited number of preclinical studies available to date.44 The skewed distribution of nanoparticle platforms should not be regarded as an indication of their intrinsic value. Instead, it is a reflection of the current research status. Nanoparticle-Based Gene and Epigenetic Therapy Therapeutic DNAs, miRNAs, miRNA inhibitors, lncRNAs, siRNAs, shRNAs, and epigenetic regulatory drugs have been proven to play therapeutic roles in cardiac hypertrophy.272 However, there are some significant challenges, including the instability of nucleic acids due to enzymatic degradation in the circulation273 and insufficient cardiac targeting ability.274 Moreover, inefficient endosomal escape is a critical bottleneck that restricts the therapeutic efficacy of nucleic acid-based therapies, as nucleic acids internalized by target cells are often trapped within endosomes and subsequently degraded in lysosomes before reaching their functional sites.275 Nanoparticle-based delivery platforms provide a potential strategy to address these challenges by protecting nucleic acids from enzymatic degradation,276 enabling targeted delivery through surface functionalization,277 and facilitating intracellular cargo release by promoting endosomal escape via the proton sponge effect and membrane fusion.278 Therapeutic plasmid-based therapy has shown considerable promise for the treatment of pathological cardiac hypertrophy. Secretoneurin (SN) is a 33-amino-acid neuropeptide that has been reported to attenuate cardiac hypertrophy by activating the AMPK and ERK/MAPK signaling pathways and reducing oxidative stress.279,280 Intravenous administration of erythrocyte membrane-coated nanoparticles loaded with SN-encoding plasmids alleviated cardiac hypertrophy in an ISO-induced mouse model,23 providing a new strategy for cardiac gene therapy. Nanoparticle-based delivery of miRNAs and miRNA inhibitors has emerged as another promising therapeutic strategy for pathological cardiac hypertrophy. For instance, Tong et al employed milk-derived extracellular vesicles loaded with miR30d, which effectively attenuated cardiac hypertrophy in mouse models induced by Ang II, TAC, and ISO, respectively. Furthermore, they revealed that miR30d attenuates cardiac hypertrophy by downregulating the expression of G protein-coupled receptor kinase 5 (GRK5).198 Likewise, miR-182 inhibitor-loaded polymeric nanoparticles alleviated TAC-induced cardiac hypertrophy in mice by restoring FOXO3 expression.260 Moreover, miR-155 antagonist was delivered via gold nanoparticles, which reduced cardiac hypertrophy in ovariectomized diabetic mice by restoring M1/M2 polarization.125 Small interfering RNA (siRNA) is a short double-stranded RNA that mediates gene silencing through the RNA interference pathway.281 Nanoparticle-based siRNA delivery systems have shown significant efficacy in the treatment of cardiac hypertrophy. A study showed that cardiac-targeting peptide-modified small extracellular vesicles (CEVs) loaded with NOX4 siRNA reduced NOX4 expression and oxidative stress, thus attenuating cardiac hypertrophy and fibrosis in Ang II–induced hypertrophic mice.174 In addition, neutrophil membrane-coated nanoparticles delivering siRNA of lncRNA AAB attenuate cardiac hypertrophy by inhibiting ferroptosis in cardiac microvascular endothelial cells in abdominal aorta constriction-induced Wistar rats.67 In addition to nucleic acids, small molecule drugs that regulate epigenetics can also be used for the treatment of cardiac hypertrophy. For instance, Li et al developed biomimetic nanoparticles coated by platelet and erythrocyte membranes for targeted delivery of the bromodomain-containing protein 4 (BRD4) inhibitor JQ1, which effectively attenuated cardiac hypertrophy and fibrosis in both pressure overload and myocardial infarction-induced mouse models by inhibiting BRD4.22 Nanoparticle-Based Anti-Oxidative Therapy Antioxidants such as coenzyme Q10, polyphenols, and flavonoids have shown protective effects against cardiac hypertrophy.282–284 However, their application is limited by poor water solubility, low bioavailability, and short circulation time.285 Nanoparticle-based delivery platforms can overcome these limitations by improving drug solubility and prolonging systemic circulation.261 Polyphenols are a diverse group of bioactive substances with potent antioxidant activity.206 Bioactive cyclodextrin (TPCD) and tannic acid (TA) nanoparticles were effective in scavenging ROS and attenuating cardiac hypertrophy in an isoproterenol-induced mouse model.261 Curcumin, another representative polyphenolic compound, has attracted much attention for cardiovascular therapy. For example, in a monocrotaline-induced rat model, curcumin nanoparticles reduced oxidative stress and inflammatory cytokine levels, thus alleviating right ventricular hypertrophy.250 Curcumin has also been incorporated into multifunctional nanoplatforms. Prussian blue-curcumin (PB-Cur) nanozymes, formed through the coordination of curcumin with ferric ions, efficiently eliminated reactive oxygen and nitrogen species (RONS) and attenuated cardiac hypertrophy in a TAC-induced mouse model. Transcriptomic profiling suggested that these protective effects were associated with inhibition of oxidative stress signaling, including the MAPK and PI3K-Akt pathways.262 Similarly, hybrid nanoparticles integrating epigallocatechin gallate with manganese dioxide (EM NPs) synergistically cleared ROS and nitrogen oxides, reversed vascular remodeling, and alleviated right ventricular hypertrophy in a monocrotaline-induced rat model.263 Furthermore, antioxidant enzymes constitute a possible treatment strategy for cardiac hypertrophy. Liposomes co-encapsulating superoxide dismutase and fasudil reduced oxidative stress and inhibited Rho kinase-mediated vasoconstriction and vascular remodeling following intratracheal administration, thereby attenuating right ventricular hypertrophy in monocrotaline-induced rats.264 ROS-responsive nanoparticles often possess intrinsic ROS-scavenging properties. For example, ROS-responsive nanoparticles designed for the delivery of soluble death receptor 5 fusion protein (sDR5-Fc) efficiently scavenged ROS through their peroxyoxalate bonds while simultaneously releasing sDR5-Fc, thereby significantly alleviating cardiac hypertrophy and fibrosis in a rat model of myocardial ischemia-reperfusion injury.81 Moreover, carbon-based nanoparticles have also shown therapeutic potential in cardiac hypertrophy. For example, sulfur-doped carbonized polymer dots alleviated isoproterenol-induced cardiac hypertrophy by scavenging ROS, restoring mitochondrial function, and reducing collagen deposition.145 Nanoparticle-Based Anti-Inflammatory Therapy Conventional anti-inflammatory medicines, such as natural substances and immunosuppressants, have demonstrated potential therapeutic potential in cardiac hypertrophy.286,287 However, the application of anti-inflammatory medicines is often limited by insufficient cardiac targeting and systemic side effects such as immunosuppression.288 To overcome this bottleneck, nanoparticle-based delivery systems have emerged. Nanoparticles may significantly increase the accumulation of drugs in hypertrophic myocardial tissues due to their unique physical and chemical properties and surface functionalization.266 This strategy reduces systemic side effects while also precisely intervening in the inflammatory signaling network within hypertrophic myocardium, thus offering new strategies for delaying the progression of cardiac hypertrophy.254 Anti-inflammatory phytochemicals are often delivered by liposomal and polymeric nanoparticles. For instance, in an ISO-induced Wistar rat model, oral administration of liposomes encapsulating resveratrol significantly reduced the level of TNF-α while upregulating Bcl-2 and downregulating BAX expression, thereby exerting anti-inflammatory and anti-apoptotic effects.259 Likewise, in a mouse model of myocardial infarction, intravenously administered berberine-loaded liposomes preserved cardiac function and attenuated adverse ventricular remodeling by anti-inflammatory effects.265 Adverse cardiac remodeling also can be treated with immunosuppressive drugs like methotrexate and rapamycin. For instance, methotrexate encapsulated in lipid-core nanoparticles (LDE-MTX) reduced cardiac hypertrophy and fibrosis in a rat model of myocardial infarction induced by left anterior descending (LAD) coronary artery ligation. Mechanistically, LDE-MTX enhanced myocardial methotrexate uptake, promoting adenosine release and subsequent vascular endothelial growth factor (VEGF) upregulation through adenosine A2A and A2B receptor signaling in cardiomyocytes and macrophages.266 Furthermore, co-delivery of rapamycin and myocardial infarction-associated antigens via liposomal nanoparticles promoted antigen-specific regulatory T cell expansion and M2 macrophage polarization, thereby suppressing excessive inflammation and attenuating cardiac hypertrophy in mice induced by permanent ligation of the LAD.254 Additionally, metallic nanoparticles have outstanding anti-inflammatory qualities. PEG-coated gold nanoparticles (AuNPs) have been shown to reduce isoproterenol-induced cardiac hypertrophy and inflammation in mice by suppressing the expression of β1-adrenergic receptors and blocking the ERK1/2 signaling pathway.119 Moreover, biomimetic nanoparticles represent a new approach for anti-inflammatory therapy. Interleukin-5-carrying neutrophil membrane-coated PLGA nanoparticles serve as immunomodulatory delivery systems and cytokine-sequestering decoys, encouraging M2 macrophage polarization and lowering post-ischemic inflammation to alleviate cardiac remodeling.24 Nanoparticle-Based Anti-Fibrotic Therapy Anti-fibrotic drugs are important therapeutic options for intervening in cardiac fibrosis.289 However, the application of anti-fibrotic drugs is limited by poor tissue selectivity and insufficient accumulation at fibrotic lesions.290 The nanoparticle delivery system can achieve precise drug delivery by targeting activated cardiac fibroblasts, improving the therapeutic efficacy of anti-fibrotic treatment.93,290 Nanocarriers have effectively facilitated the delivery of natural compounds possessing anti-fibrotic effects. Macrophage membrane-coated PLGA nanoparticles infused with lutein might mitigate pressure overload-induced cardiac fibrosis, likely via inhibition of the IL-11/ERK signaling pathway.179 Similarly, self-assembled nanoparticles generated by the co-decoction of Astragalus membranaceus and Angelica sinensis mitigated isoproterenol-induced cardiac fibrosis in mice by inhibiting collagen deposition and endothelial-to-mesenchymal transition.267 Therapies aimed at myocardial fibroblasts have emerged as a promising strategy for addressing cardiac fibrosis. For instance, fibroblast-targeted extracellular vesicles loaded with TGF-β1 inhibitor GW788388 effectively inhibited the TGF-β1/Smad3 signaling pathway, significantly reducing isoproterenol-induced myocardial fibrosis.93 Endogenous bioactive molecules such as cholecystokinin octapeptide (CCK‑8) and melatonin have been formulated into nanoparticles for anti‑fibrotic therapy. Phospholipid-shell nanoparticles containing CCK-8 and oxygen reduced hypoxia, inflammation, and fibrosis following ischemia-reperfusion.209 Melatonin‑loaded magnetic nanoparticles functionalized with a cardiac‑homing peptide, combined with external magnetic guidance, delivered the payload specifically to hypertrophic myocardium and reduced fibrosis by downregulating the TGF‑β1/Smad3 pathway in pressure overload-induced mouse models.205 Furthermore, alternative routes of administration, such as inhalation, represent an innovative strategy. Weng et al created an inhalable cardiac-targeting peptide-modified calcium phosphate nanoparticle loaded with the PDE10A inhibitor TP-10, which successfully reduced pressure overload-induced cardiac fibrosis in mice by blocking cardiomyocyte hypertrophy and cardiac fibroblast activation through cAMP/AMPK and cGMP/PKG signaling pathways, respectively.204 Challenges for the Clinical Translation of Nanoparticle-Based Strategies in Pathological Cardiac Hypertrophy Although nanoparticle-based treatments for pathological cardiac hypertrophy have made considerable preclinical advances,44 their clinical translation still faces significant challenges. The long-term biosafety of nanoparticles is the primary bottleneck to their clinical translation. Previous studies indicated that silica nanoparticles and carbon nanotubes might induce cardiotoxicity or asbestos-like carcinogenic effects, respectively.31,291,292 However, most current preclinical studies lack long-term toxicity assessments. Therefore, it is urgent to carry out long-term safety research in large animal models, including systematically monitoring the accumulation dynamics of nanoparticles in the liver, spleen, heart, kidney, and other organs, identifying the types of degradation products and clearance pathways, and tracking long-term pathological indicators such as chronic inflammation, fibrosis, and DNA damage. Moreover, the targeting efficiency of nanoparticles in cardiac tissue is still far from the ideal level. Nanoparticles predominantly accumulate in the liver and spleen, resulting in lower nanoparticle accumulation in the heart. This challenge is related to the absence of the EPR effect in myocardial tissue.33,34 Even if an active targeting strategy is adopted, its effect is often restricted by multiple factors such as protein corona formation,35 ligand saturation,293 and competition with endogenous ligands.294 These obstacles collectively highlight the urgency of optimizing nanoparticle design and developing new targeted delivery systems to improve cardiac targeting efficiency. In addition, the challenges associated with manufacturing, quality control, and regulatory evaluation should not be ignored. The scale-up of nanoparticle production is still challenging, as most preparation methods are based on complex multistep procedures that are tough to scale up,37 particularly for biomimetic nanoparticles with more sophisticated manufacturing procedures. Moreover, the lack of harmonized standards for nanoparticle characterization, manufacturing process control, and quality assessment remains a major obstacle to ensuring batch-to-batch consistency and reproducibility.295 Furthermore, nanoparticle-based therapies present additional regulatory challenges, since the current regulatory frameworks were mainly developed based on conventional pharmaceutical products and may not fully address the unique physicochemical complexity and biological behaviors of nanos.296 For nanoparticle-based therapies, the lack of fully established and globally harmonized criteria for preclinical safety evaluation, long-term risk assessment, and benefit-risk assessment hinders regulatory decision-making and clinical translation.297 Future research should focus on overcoming such obstacles and facilitating the systematic translation of nanoparticle-based therapies from bench to bedside. In particular, efforts should be devoted to optimizing or simplifying the manufacturing process to facilitate large-scale production, to establishing standardized quality assessment systems, and to designing regulatory evaluation frameworks, including preclinical safety, pharmacokinetics, biodistribution, and long-term risk assessment. Finally, the administration routes and patient compliance represent additional challenges to clinical translation. Currently, nanoparticle therapy mainly relies on intravenous injection. For chronic treatment of cardiac hypertrophy, regular injection increases the risk of infection and reduces the compliance of patients. Therefore, alternative administration routes are urgently needed. Oral administration is limited by the intestinal barrier and first-pass metabolic effects.298 Transdermal administration is subject to the low permeability of the skin.299 Although inhalation administration can take advantage of its structural advantages to bypass liver metabolism and achieve cardiac-targeted delivery,204 its long-term safety, device operation, and dose precision remain unresolved concerns. Collectively, there is an urgent need to refine current administration routes and develop patient-oriented delivery approaches to facilitate the clinical translation of nanoparticle-based therapies. Conclusions and Perspectives In this review, we have highlighted the therapeutic potential of nanoparticle-based therapeutic strategies in pathological cardiac hypertrophy. The therapeutic advantages of nanoparticle-based strategies in pathological cardiac hypertrophy can be categorized into three major aspects. First, in terms of pathological mechanism modulation, nanoparticles possess the capacity to target the key processes involved in cardiac hypertrophy, including transcriptional regulation,22 signaling pathways,119 oxidative stress,261 inflammatory responses,266 and fibrosis.179 Such wide regulatory capacity might overcome the limitations of conventional therapies that are often unable to precisely intervene at the molecular scale. Second, both active targeting and biomimetic targeting strategies may enhance the accumulation of therapeutic agents in hypertrophic myocardial tissues for myocardial targeting, thus overcoming the limitations of conventional treatments, such as poor cardiac distribution and high systemic exposure.23,125 In the therapeutic efficacy aspect, nanoparticle-based strategies have shown the potential to promote the restoration of myocardial structure and function, providing a promising way to reverse pathological cardiac remodeling, which is difficult to achieve by conventional therapies. However, the above findings need to be interpreted with caution. All the studies discussed in this paper have been conducted in mouse or rat models, and no nanoparticle-based therapy for pathological cardiac hypertrophy has been brought to clinical trials.300 There are noteworthy differences in heart rate, calcium ion handling,301 myosin subtypes,302 and immune metabolism303 between rodents and humans. This situation might mean that conclusions based on animal experiments cannot be transferred to humans. Existing studies tend to have relatively small sample sizes of animals and short observation periods. Furthermore, there is great diversity among studies in terms of animal models, administration methods, and efficacy evaluation indicators. Such variability limits the comparability of research results and the evaluation of long-term safety.304 Moreover, different design strategies of nanoparticles exhibit distinct advantages and limitations, and the selection depends on specific therapeutic needs. For material platforms, organic nanoparticles usually have good biocompatibility and a comparatively mature foundation for clinical translation.184 However, despite these favorable characteristics, challenges including formulation stability and manufacturing complexity, remain to be addressed to achieve broader clinical application.172 In contrast, inorganic nanoparticles have unique advantages owing to their intrinsic antioxidant properties and enzyme-mimetic activities.119 However, concerns regarding long-term biosafety, biodegradation, and potential accumulation may restrict their clinical translation.32 Biomimetic nanoparticles combine good biocompatibility with inherent targeting properties of biological components.22 Nevertheless, challenges related to large-scale manufacturing, batch consistency, and quality control remain important barriers for their clinical application.181,182 For the targeting strategies, active targeting improves the specificity of delivery via ligand-receptor recognition, although its efficiency may be influenced by factors such as protein corona formation.35 Biomimetic targeting utilizes natural biological components for multivalent recognition and reduced immune recognition. These strategies have complementary advantages, and they can be further optimized by rational integration.198 In addition, stimuli-responsive release strategies enable spatiotemporally controlled drug delivery by leveraging pathological microenvironmental cues, thus improving therapeutic efficacy and reducing nonspecific exposure.81 However, pathological cardiac hypertrophy involves complex pathological processes, and a single design strategy is unlikely to comprehensively address the complex nature of the disease. Based on current evidence, the combination of advantageous material platforms, complementary targeting strategies, and stimuli-responsive release mechanisms to construct multifunctional nanoparticle platforms may be a highly promising direction for improving therapeutic efficacy and facilitating future clinical translation. Future efforts should focus on the following three key aspects. First, systematic evaluation of nanoparticle-based therapies in large animal models is essential, along with comprehensive evaluations of pharmacokinetics, biodistribution, and long-term biosafety. Second, further optimization of cardiac targeting strategies and administration routes, coupled with the development of scalable manufacturing methods and standardized quality control systems, is required to bridge the gap between preclinical promise and clinical practice. Third, emerging artificial intelligence (AI)-assisted approaches may provide new opportunities for the rational design and optimization of nanomedicine platforms for cardiac therapy. By integrating multidimensional information, including nanoparticle physicochemical properties, biological interactions, pharmacokinetic profiles, and therapeutic outcomes, AI-driven computational models, including machine learning and deep learning algorithms, could facilitate the prediction of nanoparticle performance, optimization of formulation parameters, improvement of targeting strategies, and acceleration of clinical translation.305–307